RedHill Biopharma Ltd.RDHL

NasdaqHealthcarePharmaceutical Preparations

Price (close)

$0.52

Market cap

$3.2M

P/E

—

Revenue (FY)

$8.0M

Net income

-$8.3M

Dividend yield

—

1-year total return

-68.5%

Net margin

-102.8%

Revenue growth

23.2%

Debt / equity

—

What RedHill Biopharma Ltd. does.

We are a specialty biopharmaceutical company, primarily focused on U.S. development and commercialization of drugs for GI diseases, infectious diseases and oncology. Our primary goal is to become a leading specialty biopharmaceutical company.

We are currently focused primarily on the advancement of our development pipeline of clinical-stage therapeutic candidates. We also commercialize our GI-related product, Talicia ® (omeprazole, amoxicillin, and rifabutin) in the U.S. in partnership with Cumberland, and continue to explore our strategic plans for other potential products and activities.

Among our therapeutic candidates, we are exploring opaganib as a potential treatment for various conditions, including the treatment of several cancers such as prostate cancer, cholangiocarcinoma and chronic lymphocytic leukemia; virus-induced acute respiratory distress syndrome (ARDS), informed by data from a Phase 2/3 clinical study in COVID-19, Ebola and other viral infections; as well as metabolic disorders, including diabetes, obesity and nuclear radiation protection. Furthermore, we are investigating RHB-107 (upamostat) as a potential treatment for COVID-19 and other viruses as part of pandemic preparedness, including influenza.

Revenue and profit, by fiscal year.

Fiscal year	2019	2020	2021	2022	2023	2024
Revenue	$6.3M	$64.4M	$85.8M	$61.8M	$6.5M	$8.0M
Net income	-$42.3M	-$76.2M	-$97.7M	-$71.7M	$23.9M	-$8.3M
Free cash flow	-$40.9M	-$49.0M	-$65.2M	-$29.4M	-$35.8M	-$9.4M

More on RDHL.

Figures from RedHill Biopharma Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.